TXG · Investment summary · as of 4 August 2026
Priced for an operating path the record does not support
Business type: Inflection · scaling but economically observable
The operating path required by today's price is not achievable on the evidence.
At $47.01, TXG requires a 57% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 1%.
The market's disagreement with us is about terminal MARGIN, not growth.
We are not more bearish than the Street on the business - our 15.0% built terminal EBIT margin is above the ~3.9% net margin the Street's FY2027 EPS implies. We are more bearish than the PRICE.
The value rests on an exit multiple of 8.3x, a terminal operating margin of 15% and a 10.6% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Atera ships in H2 2026 into an installed base whose instrument revenue has already fallen 39% (FY2025, to $56.8m from $92.7m) after falling in FY2024, with academic/NIH funding pressure and China weakness as the named causes of the placement stall.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The market's disagreement with us is about terminal MARGIN, not growth. |
| What do we forecast? | Revenue growth of 1% demonstrated; a terminal operating margin of 15%; an exit multiple of 8.3x. |
| What does Street forecast? | Consensus: current-year earnings per share $0.00. |
| Where do we differ? | We are not more bearish than the Street on the business - our 15.0% built terminal EBIT margin is above the ~3.9% net margin the Street's FY2027 EPS implies. We are more bearish than the PRICE. On terminal margin, the difference between what the price requires and what the business has demonstrated is -149.3 percentage points. |
| What is it worth? | Twelve-month target $40.47, -14% from the struck price. Scenario-weighted expected return net of costs -13.9%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
Date not announced — no dated event that would resolve the disagreement is on file
Atera ships in H2 2026 into an installed base whose instrument revenue has already fallen 39% (FY2025, to $56.8m from $92.7m) after falling in FY2024, with academic/NIH funding pressure and China weakness as the named causes of the placement stall. If Atera placements do not restart the razor-blade engine, consumables - $507.2m of $596.7m of FY2025 products-and-services revenue, i.e. 85% - roll over on an ageing installed base. Revenue settles at $550-600m with no path to positive EBIT, the cost-out reaches its floor, and the multiple reverts to its 1-year average of 3.45x EV/sales.
Estimated probability 35%, against the 17% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit when the forward 12-month expected return falls below the E[R] > 0 net-of-costs hurdle, or when price reaches the 12-month base target of $40.47. On approach to the $40.47 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Atera ships in H2 2026 into an installed base whose instrument revenue has already fallen 39% (FY2025, to $56.8m from $92.7m) after falling in FY2024, with academic/NIH funding pressure and China weakness as the named causes of the placement stall. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Met | Is the house-versus-Street disagreement identified and quantified? |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -149.3 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: atera ships in H2 2026 into an installed base whose instrument revenue has already fallen 39% (FY2025, to $56.8m from $92.7m) after falling in FY2024, with academic/NIH funding pressure and China weakness as the named causes of the placement stall. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $37.92, which forces an immediate review.